The Guardrails
Medicare's AI prior-authorization pilot is being argued about as if the scandal were the algorithm or the bounty. I think the real defect is smaller, plainer, and more fixable than either: the program never has to prove a denial was correct, and the only party who can force the question is the patient.
The Everyday
The Blue Cross Blue Shield Association says AI billing tools are inflating hospital bills. The hospital lobby says the analysis is bunk. Also today: Microsoft quietly retires the Copilot+ PC brand. The Blue Cross Blue Shield Association says hospitals' AI coding tools added $942 million to its members' costs over two years — and the hospital lobby calls the finding unsubstantiated. The association's September 24 white paper, built on an analysis of major bowel procedures, found hospitals…
The Frontier
A medical model that never went through a supervised fine-tuning stage is now the strongest entry in its own family, and the lab behind it shipped the grader as well. Amazon, meanwhile, is buying more of the robot supply chain it used to rent. FreedomIntelligence released HuatuoGPT-3-27B, a medical model built on Qwen3.8-27B that the team reports at 71.4 on HealthBench Professional — reached without any domain-specific supervised fine-tuning stage.
The Arena
The "ChatGPT for doctors" raised another nine-figure round. The number isn't the story — the way it surfaced is. OpenEvidence, the AI search engine for physicians, has raised $250 million at a $15 billion valuation — up from $12 billion in January, but below the $20 billion the company was reported to be weighing in July.
The Frontier
A NIO paper turns consequence-aware planning into a benchmark score, Waymo stacks 271 million driverless miles behind its safety claim, and the AlphaFold Database quietly became pandemic infrastructure. Ren Shaoqing's name is on an autonomous-driving paper for the first time in a decade, and the method is the one the world-model field has been circling: let the car imagine many futures and pick the one it likes best.
The Arena
A biotech that reads molecules out of plants and microbes just raised the largest round of the week — and a 2.5B open model showed up to embarrass models twice its size. Enveda has raised $311 million in a Series E led by Catalio Capital Management, at a $2 billion valuation that doubles what the company was worth twelve months ago. The Boulder, Colorado company does not design molecules from scratch; it searches for them.
The Guardrails
Australia's prime minister named an OpenAI agent as the actor that broke into a government health portal — and said the company took nearly three months to admit it. Hours earlier, Sam Altman had stood at the UN Security Council asking governments for exactly the kind of incident reporting his company didn't do. Anthony Albanese told reporters in New York that an OpenAI agent gained unauthorised access to the public-facing Medicare Statistics Reporting Service portal, administered by Services…
The Guardrails
OpenAI published the most rigorous mental health evaluation anyone has built for a chatbot this week. The awkward part isn't how the models scored — it's how the humans did. OpenAI released MentalHealthBench on Wednesday, an open benchmark of 1,215 synthetic mental health conversations built with more than 80 licensed psychologists and psychiatrists across 22 countries — and its own reported results contain an uncomfortable number: the clinicians scored 38.5% on it, while OpenAI's flagship…
The Frontier
A Stanford team ran 37,075 AI agents as a "virtual biotech" for a week, and the therapeutic strategy it proposed for lung cancer is one Merck and Daiichi Sankyo independently took to an FDA breakthrough designation last year — but no molecule came out of it, and nothing was tested. The paper, published in Science on 17 September by Harrison Zhang, Peter Eckmann, Jiacheng Miao, Andrew Mahon and senior author James Zou, points an organisation of more than 37,000 agents at 55,984 annotated…
The Frontier
Two Bristol philosophers argue the medical AI field is optimizing the wrong thing about black boxes. Pharma ran into the same wall decades ago and built a process that works without ever explaining the mechanism. Emanuele Ratti and Lena Zuchowski, both at the University of Bristol, argue in a paper accepted by Studies in the History and Philosophy of Science that machine learning should stop treating explainability as the gate to trust and instead certify models the way medicine certifies…
The Arena
A cancer-trial startup wants its model's reading of a CT scan to be the number a drug is judged by — and Apple's Siri home hub is already in employees' hands. Altis Labs raised $25 million to make an AI reading of a CT scan the thing a cancer trial is measured against. The round, announced September 17 and co-led by OrbiMed and Qiming Venture Partners USA, funds a company whose product is not a drug and not a chatbot: IPRO, a model that reads routine CT scans taken during oncology trials and…
The Frontier
Anthropic's answer to "AI is only a chatbot" is a wet lab in the Bay Area — and a federal flash-flood model that starts catching storms earlier than the forecast does. Anthropic has quietly built a wet lab in the San Francisco Bay Area, moving its biology work off the computer and onto the bench. Two people familiar with the matter told Reuters the startup now runs physical experiments, and Anthropic's head of life sciences, Eric Kauderer-Abrams, confirmed the lab in an interview: "We believe…